Financial Health Assessment: Galson Sciences Limited

1. Financial Health Score: B

Explanation: The company demonstrates a reasonably healthy financial constitution with solid liquidity and a positive recovery trajectory. However, the dramatic balance sheet contraction between 2020-2021 (likely a group restructuring) and the absence of profit & loss visibility prevents a higher grade. The patient is stable and recovering, but the medical history includes a significant "surgical event" that warrants ongoing monitoring.

2. Key Vital Signs

Vital Signs Interpretation

Healthy Cash Flow: The cash position has nearly doubled year-on-year, indicating strong cash generation or receipt of significant payments. This is like a patient whose blood pressure has stabilized at healthy levels after a period of concern.

Rising Liabilities - A Symptom to Monitor: Current liabilities have increased by 83%, significantly outpacing the 73% growth in current assets. This is akin to a slightly elevated heart rate – not immediately dangerous, but requiring observation. Key contributors: - Accrued expenses jumped from £403k to £865k (114% increase) - Trade creditors rose from £79k to £222k (179% increase) - Deferred income grew from £111k to £265k (137% increase)

Positive Working Capital: Net current assets of £816k provide a comfortable buffer, equivalent to having healthy reserves in the immune system.

3. Diagnosis

The Historical "Surgical Event" (2020-2021)

The most striking feature of this company's financial medical history is the dramatic decline in net assets between 2020 and 2021:

This represents an extraordinary contraction – equivalent to losing 84% of the company's net worth in a single year. However, context is critical:

• The company is controlled by Egis Industries SAS (a French multinational engineering group)
• "Amounts owed to group undertakings" appear in the accounts, confirming group relationships
• The company continued trading and has since recovered

Diagnosis: This was almost certainly a group restructuring event – a deliberate "financial surgery" where assets (likely cash) were extracted by the parent company through dividends or intercompany transfers. This is common in group structures and does not necessarily indicate business failure. The patient didn't haemorrhage; the blood was deliberately transferred.

Current Business Health

Strengths: - Solvent: Net assets are positive and growing - Liquid: Current ratio of 1.52:1 provides comfortable headroom - Cash-rich: £1.24M cash represents 52% of current assets - Growing: Employee count increasing (26→29) suggests business expansion - Well-capitalised: Minimal share capital (£860) but substantial retained earnings (£825k)

Areas of Concern: - Contract recoverability: £658,872 in "amounts recoverable on contracts" represents 57% of total debtors. This is a significant sum that depends on contract completion and client acceptance – like having a large portion of income tied up in pending insurance claims. - Rising accrued expenses: The near-doubling of accrued expenses could indicate cash flow timing issues or growing obligations that will need settlement. - No P&L visibility: As a small company filing filleted accounts, profitability metrics are unavailable. We cannot assess margins, revenue trends, or operational efficiency. - Deferred income growth: While not inherently negative (it represents advance payments), the 137% increase suggests the company is receiving more upfront payments, which creates future delivery obligations.

Balance Sheet Quality Assessment

The asset composition reveals:

The company is essentially a people-and-cash business with minimal fixed assets, which is typical for consulting firms. The heavy reliance on contract recoveries is a characteristic risk in the engineering consulting sector.

4. Prognosis

Short-term Outlook: Stable with Positive Indicators

The company appears to be in a recovery phase following the 2021 restructuring. Key positive signals: - Net assets have grown 55% from the 2022 trough - Cash generation is strong - Workforce is expanding

Medium-term Risks

1. Group Dependency: As a subsidiary of Egis Industries, strategic decisions may be driven by group interests rather than standalone company health
2. Contract Collection Risk: The significant "amounts recoverable on contracts" could become problematic if clients dispute or delay payments
3. Liability Growth: If current liabilities continue to outpace asset growth, working capital could become constrained

Long-term Considerations

The company's long-term prognosis depends heavily on its relationship with its French parent. The reduction in "amounts owed to group undertakings" (from £116k to £36k) suggests the group is not using this company as a financing vehicle, which is positive.

5. Recommendations

Immediate Actions

1. Contract Recoverability Review: Conduct a thorough aged analysis of the £658k in contract recoveries. Assess the probability of collection and identify any provisions needed. This is like conducting diagnostic imaging on a potential blockage – early detection prevents complications.

2. Accrued Expenses Investigation: Understand why accrued expenses nearly doubled. If this represents delayed payments to suppliers or accumulated obligations, a payment schedule should be established to prevent cash flow pressure.

3. Deferred Income Management: Ensure the company has capacity to deliver on the £265k of deferred income obligations. This represents future work that must be completed.

Medium-term Strategies

4. Working Capital Management: While the current ratio is healthy, monitor the trend of liabilities growing faster than assets. Consider implementing tighter working capital controls.

5. Cash Deployment Strategy: With £1.24M in cash, evaluate whether some funds could be better deployed in business growth or returned to shareholders (considering the group structure).

6. Debtor Days Analysis: With trade debtors of £405k and likely annual revenue in the several million pound range (based on 29 employees and the balance sheet), target debtor days of no more than 45-60 days.

Ongoing Monitoring

7. Group Transaction Transparency: Continue monitoring intercompany balances and transactions to ensure terms are fair and not detrimental to the UK entity.

8. Quarterly Health Checks: Given the volatility in the balance sheet history, implement quarterly financial reviews rather than relying solely on annual accounts.

Summary Dashboard